Skip to main content
Figure 2 | BMC Public Health

Figure 2

From: Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan

Figure 2

The number of annual incident and prevalent users for ACEIs and ARBs. (a) Annual incident and prevalent users of renin-angiotensin drugs (ACEIs and/or ARBs); (b) Annual incident and prevalent users of ACEIs or ARBs; (c) Annual incident and prevalent users of both drugs (i.e., ACEIs and ARBs used concurrently or subsequently); (d) Annual prevalent ARB users and cumulative incident ARB users. ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.

Back to article page